StemCells (STEM) PT Cut to $3 at Maxim Group
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- US futures steady as oil retreats ahead of earnings deluge, Fed decision
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil slips but stays near six-month highs on Saudi attacks
- BofA flags further downside risk for stocks, yields and dollar
StemCells, Inc. Announces Strategic Realignment
December 23, 2015 8:05 AM ESTNEWARK, Calif., Dec. 23, 2015 (GLOBE NEWSWIRE) -- StemCells, Inc. (NASDAQ: STEM), a world leader in the research and development of cell-based therapeutics for the treatment of disorders of the central nervous system, today announced a strategic realignment to fully focus the Companys resources on its proprietary HuCNS-SC® platform technology for the treatment of chronic spinal cord injury (SCI).
Evidence of efficacy from the Companys ongoing clinical trials in chronic SCI offers therapeutic promise to restore lost function previously considered unrecoverable. StemCells recently reported a pattern of improvements in both... More



